An oral once-daily medication that blocks a cholesterol-transfer protein, lowering the harmful cholesterol-carrying particles most tied to heart disease plus a stubborn inherited risk particle. The first in a long-troubled drug family to pair strong, reproducible lowering with a clean short-term safety record. Proof that this prevents heart events remains short-term and incomplete. (Full Review)

Protocol

Standard Regimen

10 mg once daily

Fixed low oral dose carried through the entire phase 3 program

Positioning

Add-on to statin

On top of maximally tolerated statin therapy, with or without ezetimibe

Administration

Single daily dose

Timing non-critical given long half-life; not split; food had only modest effect on absorption

Time to effect

Lipid Lowering

8–12 weeks

Lipid changes appear within weeks and are near-maximal by around 8–12 weeks

Cardiovascular Benefit

Months to years

Event reduction accrues over months to years, consistent with the delayed effect seen after the first six months

Washout After Stopping

Subsequent weeks

Lipids return toward pre-treatment levels over subsequent weeks as the long half-life washes out

Benefits

High: LDL cholesterol reduction; apolipoprotein B and non-HDL cholesterol reduction

Medium: Lipoprotein(a) reduction; reduction in major coronary events

Low: Reduction in new-onset type 2 diabetes; attenuation of kidney function decline

Speculative: Alzheimer's disease biomarker modification; broader longevity and age-related disease prevention

Contraindications

Pregnancy and breastfeeding

Severe hepatic impairment (Child-Pugh Class C)

Known hypersensitivity

Key Interactions

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin)

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin)

Statins (atorvastatin, rosuvastatin)

St. John's wort; grapefruit

Supplements with additive lipid effects (red yeast rice, plant sterols, soluble fiber, berberine)

Ezetimibe; PCSK9 inhibitors (evolocumab)

Risk & Side Effects

High: Generally placebo-like tolerability (absence of major signal)

Medium: Mild, non-specific adverse events

Low: Blood pressure and aldosterone effects (class legacy concern); small rise in total cholesterol and uncertain HDL meaning

Speculative: Unknown long-term and rare risks; theoretical effects on steroid hormone and adrenal pathways

Monitoring

Marker	Target	Why
Apolipoprotein B (ApoB)	< 60–80 mg/dL for high-risk optimization	Best single measure of atherogenic particle number; primary target
LDL-C	As low as feasible; often < 55 mg/dL in very-high-risk	Established primary driver of atherosclerosis
Lipoprotein(a) [Lp(a)]	< 75 nmol/L (roughly < 30 mg/dL)	Independent, largely genetic risk factor obicetrapib can lower
Non-HDL cholesterol	< 80–100 mg/dL for high-risk	Captures all atherogenic cholesterol; useful when triglycerides vary
HDL cholesterol	Expected to rise markedly on treatment	Confirms pharmacologic effect; not itself a treatment target
ALT / AST (liver enzymes)	Within normal laboratory range	Safety monitoring given hepatic metabolism

Cadence: Baseline before starting; recheck lipid and apolipoprotein B panel at about 8–12 weeks, then every 6–12 months once stable; liver enzymes at baseline and periodically.

Qualitative Assessment

General tolerability (absence of new headache, gastrointestinal, or non-specific symptoms)
Sustained adherence and absence of side effects prompting discontinuation
Overall energy and well-being unchanged

Obicetrapib for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment